Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced agreements with three leading medical radioisotope manufacturers NorthStar Medical Radioisotopes LLC, Niowave, Inc, and TerraPower LLC, for preclinical, clinical, and commercial supply of Actinium-225.

The three agreements provide Aktis with a portfolio of suppliers that utilize varied techniques to produce high quality Actinium-225, and enhance the Company’s ability to ensure just-in-time delivery of finished targeted radioconjugates to healthcare providers for administration to patients. NorthStar’s approach to Actinium-225 production is to utilize non-uranium, electron accelerator-based production methods; Niowave builds and operates superconducting electron accelerators to produce Ac-225 and other radioisotopes, whereas TerraPower uses a Thorium-229 generator. These agreements are a part of broader ongoing efforts to build and enhance Aktis’s supply access, radiomanufacturing and distribution capabilities.

To read more please visit:

Aktis Oncology Announces Actinium-225 Supply Agreements with Leading Isotope Producers

Source: Aktis